The evidence supporting pharmacotherapy is inadequate, as the majority of clinical trials using drugs such as GLP-1 agonists and SGLT2 inhibitors have primarily included obese individuals, resulting in the efficacy and safety of these treatments for lean NAFLD remaining largely unverified (16). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.